GlassScriptPhysician profile
Heather J Dalton
NPI 1033373139
$25,610.25
in general payments reported to CMS, 2019-2025
56 companies · $731 in 2025
The $731 reported for 2025 was more than what a typical Gynecologic Oncology provider received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,589 · 2020: $4,664 · 2021: $15K · 2022: $2,610 · 2023: $280 · 2024: $473 · 2025: $731.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,484.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,483.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $8,000.00 | 2021 | |
| Glaxosmithkline, LLC. | $5,633.20 | 2020-2025 | Zejula, Jemperli |
| Astrazeneca Pharmaceuticals LP | $3,153.84 | 2019-2025 | Imfinzi |
| Eisai INC. | $2,340.00 | 2022 | |
| Seagen INC. | $2,047.27 | 2019-2021 | |
| Tesaro, INC. | $920.61 | 2019 | |
| Clovis Oncology, INC. | $653.72 | 2019-2022 | |
| Genmab U.S., INC. | $345.33 | 2021-2025 | Tivdak |
| Myriad Genetic Laboratories, INC. | $228.60 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $176.49 | 2019-2025 | Keytruda, Lynparza |
| Stryker Corporation | $138.93 | 2021 | |
| Amgen INC. | $121.24 | 2019-2021 | |
| Baxter Healthcare | $120.31 | 2022 | |
| Janssen Biotech, INC. | $115.41 | 2019-2025 | Talvey, Erleada, Tecvayli |
| Astellas Pharma US INC | $111.30 | 2023 | Veozah |
Show all 56 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Dalton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.